Early Onset Neutropenia due to Rituximab Therapy in Mantle Cell Lymphoma: A Case Report

Abstract

Cases of late onset neutropenia (LON) after rituximab therapy have been documented, but few cases have been documented of early onset neutropenia (EON). We present a case report of a patient with mantle cell lymphoma who presented with EON, only 6 days after initiation of rituximab therapy, notable for the shortest duration to EON ever reported in literature. Throughout this paper, we explore the potential pathogenesis and incidence of EON with the help of our unique case.

An Update on the Incidence, Risk Factors and Mechanisms of Rituximab- Associated Neutropenia

“…Refractory oral involvement 375 mg/m 2 × 4 dose 18 0.09×10 9 /L G-CSF, broadspectrum antibiotics Nelson [23] 2021 Aguiar-Bujanda [19] 2015 Pneumonia, sepsis and hemorrhagic fever 1 Bronchitis 1 Knight [26] 2016 [27] 2017 BCL patients receiving ASCT CT 315/-/-92/29%/-/-0.4×10 9 /L (range 0.0-0.9×10 9 /L) 91 (range 33-166) 14 (range 1-233)…”

“…RAN is uncommon, with the majority of cases being LON rather than EON [ 8 , 12 ]. This makes EON extremely rare, with only 8 cases reported [ 9 , 17 , 20 – 23 ]. Specific information on these 8 cases is presented in Table I .…”